Anthony Rowe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anthony Rowe has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Iqbal Ramzan
Faculty of Pharmacy University of Sydney NSW 2006 Australia
6 shared publications D. Emery
Faculty of Veterinary Science, McMaster Building (B14), University of Sydney, Camperdown Campus, NSW 2006, Australia
3 shared publicationsN. Sangster
School of Animal & Veterinary Sciences, Charles Sturt University, Locked Bag 588, Wagga, NSW 2678, Australia
3 shared publications- Cedric Gondro
Department of Animal Science, Michigan State University, East Lansing, MI 48824, USA
2 shared publications - Filip Braet
School of Medical Sciences The University of Sydney Sydney New South Wales Australia
2 shared publications Iqbal Ramzan
Faculty of Pharmacy, Pharmacy Bank Building (A15), Camperdown Campus, University of Sydney, Australia
2 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by Elsevier in Comparative Immunology, Microbiology and Infectious Diseases
- Vol. 130
Tracing Encephalitozoon cuniculi in a research rabbit colony - From clinical outbreak to seronegative status
- 6 September 2026
- Published by Elsevier in Comparative Immunology, Microbiology and Infectious Diseases
- Vol. 130
Open AccessTracing Encephalitozoon cuniculi in a research rabbit colony - From clinical outbreak to seronegative status
- 29 December 2025
- Published by Springer Nature in Journal of Agricultural and Environmental Ethics
- Vol. 39 (1) , 4
Why Non-invasive Animal Studies Should Seek Ethical Review
- 29 December 2025
- Published by Springer Nature in Journal of Agricultural and Environmental Ethics
- Vol. 39 (1) , 4
Why Non-invasive Animal Studies Should Seek Ethical Review
- 1 December 2022
- Published by SAGE Publications in Laboratory Animals
- Vol. 57 (3) , 224-235
Recommendations to improve use and reporting of statistics in animal experiments
Flaws in experimental statistics are a major contributor to the poor reproducibility of animal experiments. Informed decisions about whether conclusions are justified requires clear reporting of experimental data and the statistical methods used to analyse them. When data are misinterpreted, manipulated or concealed to generate publications, it creates an illusion that chance observations are robust data which confirm the hypotheses presented. Attempts to reproduce and advance such observations can propagate large areas of irreproducible science. This hinders scientific progress, erodes public support for research, damages reputations and wastes resources. This review analyses and explains recommendations to improve use and reporting of statistics in animal experiments.
- 1 December 2022
- Published by SAGE Publications in Laboratory Animals
- Vol. 57 (3) , 224-235
Recommendations to improve use and reporting of statistics in animal experiments
Flaws in experimental statistics are a major contributor to the poor reproducibility of animal experiments. Informed decisions about whether conclusions are justified requires clear reporting of experimental data and the statistical methods used to analyse them. When data are misinterpreted, manipulated or concealed to generate publications, it creates an illusion that chance observations are robust data which confirm the hypotheses presented. Attempts to reproduce and advance such observations can propagate large areas of irreproducible science. This hinders scientific progress, erodes public support for research, damages reputations and wastes resources. This review analyses and explains recommendations to improve use and reporting of statistics in animal experiments.
- 22 October 2018
- Published by Springer Nature in Journal of Agricultural and Environmental Ethics
- Vol. 31 (5) , 625-634
Should Scientific Research Involving Decapod Crustaceans Require Ethical Review?
- 22 October 2018
- Published by Springer Nature in Journal of Agricultural and Environmental Ethics
- Vol. 31 (5) , 625-634
Should Scientific Research Involving Decapod Crustaceans Require Ethical Review?
- 20 August 2018
- Published by CSIRO Publishing in Animal Production Science
- Vol. 59 (3) , 401-407
The importance of selection and reporting of the sex of experimental animals
Biased use of males and females in animal studies or omitting specific details of the sex of animals used in publications limits reproducibility, hampers the pace and likelihood of new discoveries and invites adverse events in ensuing clinical research. Hence unbiased use of males and females in animal studies and specific reporting of animal details are increasingly required by funding bodies and scientific journals worldwide. An analysis to determine how males and females are used in animal studies involving the Commonwealth Scientific and Industrial Research Organisation (CSIRO) was undertaken as part of a process to review and further support best practice. In the study 178 publications that contain animal studies and include CSIRO researchers published between January 2014 and December 2016 were analysed for the sex of animals used. The overall sex distribution was males only 26.4% (47/178), females only 15.7% (28/178), males and females 18.0% (32/178) and sex of animals unspecified 39.9% (71/178). Reasons for this distribution include species biology, farming practices and commercial relevance. Although including sex as an experimental variable provides the most information, using both sexes in an animal study requires careful consideration and planning. Furthermore, there are valid biological and experimental reasons why sex distribution in a study may not be balanced. Biological reasons include cases where the severity of disease in a given model differs between males and females, superior husbandry or production traits in one sex and hermaphroditic species that change sex with age. Examples where experiments can only be undertaken in one sex of animal include animal models of female breast cancer, female reproductive traits, male fertility studies and post-castration welfare outcomes. Where there is no biological or experimental reason for using a single sex of animal, future studies should obtain an estimate of sex effect either from the literature or with a pilot study, and experiments should be planned and reported accordingly.
- 20 August 2018
- Published by CSIRO Publishing in Animal Production Science
- Vol. 59 (3) , 401-407
The importance of selection and reporting of the sex of experimental animals
Biased use of males and females in animal studies or omitting specific details of the sex of animals used in publications limits reproducibility, hampers the pace and likelihood of new discoveries and invites adverse events in ensuing clinical research. Hence unbiased use of males and females in animal studies and specific reporting of animal details are increasingly required by funding bodies and scientific journals worldwide. An analysis to determine how males and females are used in animal studies involving the Commonwealth Scientific and Industrial Research Organisation (CSIRO) was undertaken as part of a process to review and further support best practice. In the study 178 publications that contain animal studies and include CSIRO researchers published between January 2014 and December 2016 were analysed for the sex of animals used. The overall sex distribution was males only 26.4% (47/178), females only 15.7% (28/178), males and females 18.0% (32/178) and sex of animals unspecified 39.9% (71/178). Reasons for this distribution include species biology, farming practices and commercial relevance. Although including sex as an experimental variable provides the most information, using both sexes in an animal study requires careful consideration and planning. Furthermore, there are valid biological and experimental reasons why sex distribution in a study may not be balanced. Biological reasons include cases where the severity of disease in a given model differs between males and females, superior husbandry or production traits in one sex and hermaphroditic species that change sex with age. Examples where experiments can only be undertaken in one sex of animal include animal models of female breast cancer, female reproductive traits, male fertility studies and post-castration welfare outcomes. Where there is no biological or experimental reason for using a single sex of animal, future studies should obtain an estimate of sex effect either from the literature or with a pilot study, and experiments should be planned and reported accordingly.
- Open Access
- 1 July 2016
- Published by SAGE Publications in Cell Transplantation
- Vol. 25 (7) , 1299-1317
Coencapsulation of Target Effector Cells with Mesenchymal Stem Cells Reduces Pericapsular Fibrosis and Improves Graft Survival in a Xenotransplanted Animal Model
Pericapsular fibrotic overgrowth (PFO) is a problem that thwarts full implementation of cellular replacement therapies involving encapsulation in an immunoprotective material, such as for the treatment of diabetes. Mesenchymal stem cells (MSCs) have inherent anti-inflammatory properties. We postulated that coencapsulation of MSCs with the target cells would reduce PFO. A hepatoinsulinoma cell line (HUH7) was used to model human target cells and was coencapsulated with either human or mouse MSCs at different ratios in alginate microcapsules. Viability of encapsulated cells was assessed in vitro and xenografted either intraperitoneally or subcutaneously into C57BL/6 mice. Graft retrieval was performed at 3 weeks posttransplantation and assessed for PFO. Coencapsulation of human MSCs (hMSCs) or mouse MSCs (mMSCs) with HUH7 at different ratios did not alter cell viability in vitro. In vivo data from intraperitoneal infusions showed that PFO for HUH7 cells coencapsulated with hMSCs and mMSCs in a ratio of 1:1 was significantly reduced by ~30% and ~35%, respectively, compared to HUH7 encapsulated alone. PFO for HUH7 cells was reduced by ~51% when the ratio of mMSC/HUH7 was increased to 2:1. Implanting the microcapsules subcutaneously rather than intraperitoneally substantially reduced PFO in all treatment groups, which was most significant in the mMSC/HUH7 2:1 group with a ~53% reduction in PFO compared with HUH7 alone. Despite the reduced PFO reaction to the individual microcapsules implanted subcutaneously, all microcapsule treatment groups were contained in a vascularized fibrotic pouch at 3 weeks. The presence of MSCs in microcapsules retrieved from these fibrotic pouches improved graft survival with significantly higher cell viabilities of 83.1 ± 0.6% and 79.1 ± 0.8% seen with microcapsules containing mMSC/HUH7 at 2:1 and 1:1 ratios, respectively, compared to HUH7 alone (51.5 ± 0.7%) transplanted subcutaneously. This study showed that coencapsulation of MSCs with target cells has a dose-dependent effect on reducing PFO and improving graft survival when implanted either intraperitoneally or subcutaneously in a stringent xenotransplantation setting.
- 1 July 2016
- Published by SAGE Publications in Cell Transplantation
- Vol. 25 (7) , 1299-1317
Open AccessCoencapsulation of Target Effector Cells with Mesenchymal Stem Cells Reduces Pericapsular Fibrosis and Improves Graft Survival in a Xenotransplanted Animal Model
Pericapsular fibrotic overgrowth (PFO) is a problem that thwarts full implementation of cellular replacement therapies involving encapsulation in an immunoprotective material, such as for the treatment of diabetes. Mesenchymal stem cells (MSCs) have inherent anti-inflammatory properties. We postulated that coencapsulation of MSCs with the target cells would reduce PFO. A hepatoinsulinoma cell line (HUH7) was used to model human target cells and was coencapsulated with either human or mouse MSCs at different ratios in alginate microcapsules. Viability of encapsulated cells was assessed in vitro and xenografted either intraperitoneally or subcutaneously into C57BL/6 mice. Graft retrieval was performed at 3 weeks posttransplantation and assessed for PFO. Coencapsulation of human MSCs (hMSCs) or mouse MSCs (mMSCs) with HUH7 at different ratios did not alter cell viability in vitro. In vivo data from intraperitoneal infusions showed that PFO for HUH7 cells coencapsulated with hMSCs and mMSCs in a ratio of 1:1 was significantly reduced by ~30% and ~35%, respectively, compared to HUH7 encapsulated alone. PFO for HUH7 cells was reduced by ~51% when the ratio of mMSC/HUH7 was increased to 2:1. Implanting the microcapsules subcutaneously rather than intraperitoneally substantially reduced PFO in all treatment groups, which was most significant in the mMSC/HUH7 2:1 group with a ~53% reduction in PFO compared with HUH7 alone. Despite the reduced PFO reaction to the individual microcapsules implanted subcutaneously, all microcapsule treatment groups were contained in a vascularized fibrotic pouch at 3 weeks. The presence of MSCs in microcapsules retrieved from these fibrotic pouches improved graft survival with significantly higher cell viabilities of 83.1 ± 0.6% and 79.1 ± 0.8% seen with microcapsules containing mMSC/HUH7 at 2:1 and 1:1 ratios, respectively, compared to HUH7 alone (51.5 ± 0.7%) transplanted subcutaneously. This study showed that coencapsulation of MSCs with target cells has a dose-dependent effect on reducing PFO and improving graft survival when implanted either intraperitoneally or subcutaneously in a stringent xenotransplantation setting.
- 1 January 2016
- Published by Begell House Inc. Publishers in Plasma Medicine
- Vol. 6 (1) , 67-83
Effect of Atmospheric-Pressure Plasmas on Drug Resistant Melanoma: The Challenges of Translating In vitro Outcomes into Animal Models
Atmospheric plasmas (AP) have been identified as a promising cancer therapy able to preferentially kill neoplastic cells by apoptosis. In vitro studies suggest AP-generated reactive oxygen species (ROS) as the principal triggers of apoptosis-related signalling cascades via oxidative stress and direct interference with DNA, proteins, and other cellular components. Results of this study corroborate ROS-mediated mechanism of cancer cell death, with apoptosis in AP-treated Mel-007 melanoma cells inhibited by pre-treatment of cells with the ROS scavenger NAC or the caspase inhibitor zVAD-fmk. In an effort to compare apoptosis mechanisms and evaluate the in vitro-in vivo correlation for AP-induced apoptosis, Mel-007 cells were injected subcutaneously into mice to form solid tumours and treated with AP. Histological assessment of tumours from control and AP-treated animals showed no significant difference in tumour volume, mitotic rate, and percentage of necrosis or multinucleate cells. These results are at variance with other reports of AP treatment of xenograft tumours in murine models, where a decrease in tumour size and tumour volume has been observed. These findings focus our attention on challenges associated with translating the in vitro results to corresponding in vivo outcomes, and highlight concerns about the applicability of mechanisms established in vitro to intrinsically dynamic in vivo environment.
- 1 January 2016
- Published by Begell House Inc. Publishers in Plasma Medicine
- Vol. 6 (1) , 67-83
Effect of Atmospheric-Pressure Plasmas on Drug Resistant Melanoma: The Challenges of Translating In vitro Outcomes into Animal Models
Atmospheric plasmas (AP) have been identified as a promising cancer therapy able to preferentially kill neoplastic cells by apoptosis. In vitro studies suggest AP-generated reactive oxygen species (ROS) as the principal triggers of apoptosis-related signalling cascades via oxidative stress and direct interference with DNA, proteins, and other cellular components. Results of this study corroborate ROS-mediated mechanism of cancer cell death, with apoptosis in AP-treated Mel-007 melanoma cells inhibited by pre-treatment of cells with the ROS scavenger NAC or the caspase inhibitor zVAD-fmk. In an effort to compare apoptosis mechanisms and evaluate the in vitro-in vivo correlation for AP-induced apoptosis, Mel-007 cells were injected subcutaneously into mice to form solid tumours and treated with AP. Histological assessment of tumours from control and AP-treated animals showed no significant difference in tumour volume, mitotic rate, and percentage of necrosis or multinucleate cells. These results are at variance with other reports of AP treatment of xenograft tumours in murine models, where a decrease in tumour size and tumour volume has been observed. These findings focus our attention on challenges associated with translating the in vitro results to corresponding in vivo outcomes, and highlight concerns about the applicability of mechanisms established in vitro to intrinsically dynamic in vivo environment.
- Open Access
- 1 December 2015
- Published by Springer Nature in Particle and Fibre Toxicology
- Vol. 13 (1) , 1-13
Long-term exposure to commercially available sunscreens containing nanoparticles of TiO2 and ZnO revealed no biological impact in a hairless mouse model
The application of sunscreen is a critical component of a sun-safe strategy, however the possibility of unexpected, adverse outcomes resulting from long-term use of sunscreens containing nanoparticles of titanium dioxide (TiO2) and zinc oxide (ZnO) has not yet been examined. Here, immune-competent hairless mice were exposed over a 36-week period to weekly topical applications of sunscreens containing nanoparticles of ZnO or TiO2, or no metal oxide nanoparticles, with or without subsequent exposure to ultraviolet radiation (UVR). Control groups received no sunscreen applications, with or without UVR. Mice exposed to UVR in the absence of sunscreen developed statistically significant incidences of histologically-diagnosed malignant and benign skin neoplasms, whereas no statistically significant adverse biological outcomes were found in mice treated with the sunscreens containing ZnO or TiO2 nanoparticles. Elevated levels of Ti were detected in the livers of mice treated with sunscreen containing TiO2 nanoparticles compared to untreated control, but total Zn concentrations did not significantly alter in any major organs except for the skin of mice treated with ZnO sunscreen. Exposure to UVR did not have a significant impact on examined tissue concentrations of Zn or Ti. Few to no transcriptional changes were found in ZnO or TiO2-treated groups, but mice treated with the sunscreen containing only organic filters showed substantial gene disregulation. Taken together with previous work, this long-term study provided no basis to avoid the use of sunscreens containing metal oxide nanoparticles.
- 1 December 2015
- Published by Springer Nature in Particle and Fibre Toxicology
- Vol. 13 (1) , 1-13
Open AccessLong-term exposure to commercially available sunscreens containing nanoparticles of TiO2 and ZnO revealed no biological impact in a hairless mouse model
The application of sunscreen is a critical component of a sun-safe strategy, however the possibility of unexpected, adverse outcomes resulting from long-term use of sunscreens containing nanoparticles of titanium dioxide (TiO2) and zinc oxide (ZnO) has not yet been examined. Here, immune-competent hairless mice were exposed over a 36-week period to weekly topical applications of sunscreens containing nanoparticles of ZnO or TiO2, or no metal oxide nanoparticles, with or without subsequent exposure to ultraviolet radiation (UVR). Control groups received no sunscreen applications, with or without UVR. Mice exposed to UVR in the absence of sunscreen developed statistically significant incidences of histologically-diagnosed malignant and benign skin neoplasms, whereas no statistically significant adverse biological outcomes were found in mice treated with the sunscreens containing ZnO or TiO2 nanoparticles. Elevated levels of Ti were detected in the livers of mice treated with sunscreen containing TiO2 nanoparticles compared to untreated control, but total Zn concentrations did not significantly alter in any major organs except for the skin of mice treated with ZnO sunscreen. Exposure to UVR did not have a significant impact on examined tissue concentrations of Zn or Ti. Few to no transcriptional changes were found in ZnO or TiO2-treated groups, but mice treated with the sunscreen containing only organic filters showed substantial gene disregulation. Taken together with previous work, this long-term study provided no basis to avoid the use of sunscreens containing metal oxide nanoparticles.
- 1 November 2012
- Published by Elsevier in Experimental Neurology
- Vol. 238 (1) , 29-37
l-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro
- 1 November 2012
- Published by Elsevier in Experimental Neurology
- Vol. 238 (1) , 29-37
l-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro
- 9 March 2012
- Published by Wiley in Phytotherapy Research
- Vol. 26 (12) , 1813-1816
Kavalactone Metabolism in the Isolated Perfused Rat Liver
Metabolic pathways for kavalactone metabolism in humans and rats have been identified, but more detailed description of the enzyme kinetics involved is lacking. The disposition profiles of three of the six major kavalactones (kavain, methysticin and desmethoxyyangonin) and their respective metabolites (p‐hydroxykavain, m,p‐dihydroxykavain and p‐hydroxy‐5,6‐dehydrokavain) were examined in the perfusate and bile of the isolated perfused rat liver. The metabolism of the kavalactones is first‐order in nature with similar decay half‐lives. p‐Hydroxykavain and m,p‐dihydroxykavain were the only metabolites detected in the perfusate. Kavalactone biliary excretion was negligible. Copyright © 2012 John Wiley & Sons, Ltd.
- 9 March 2012
- Published by Wiley in Phytotherapy Research
- Vol. 26 (12) , 1813-1816
Kavalactone Metabolism in the Isolated Perfused Rat Liver
Metabolic pathways for kavalactone metabolism in humans and rats have been identified, but more detailed description of the enzyme kinetics involved is lacking. The disposition profiles of three of the six major kavalactones (kavain, methysticin and desmethoxyyangonin) and their respective metabolites (p‐hydroxykavain, m,p‐dihydroxykavain and p‐hydroxy‐5,6‐dehydrokavain) were examined in the perfusate and bile of the isolated perfused rat liver. The metabolism of the kavalactones is first‐order in nature with similar decay half‐lives. p‐Hydroxykavain and m,p‐dihydroxykavain were the only metabolites detected in the perfusate. Kavalactone biliary excretion was negligible. Copyright © 2012 John Wiley & Sons, Ltd.